Anika Therapeutics (ANIK) Cash from Investing Activities Growth (1y) (2011 - 2026)
Anika Therapeutics (ANIK) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -308.05% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -41.51% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -139.86% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 129.18% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 1.71% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -366.90% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -96.43% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Anika Therapeutics | 284.33 Mn | 245.92 Mn | 21.24 Mn | -137.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -137.48% |
| Mar 31, 2026 | -174.10% |
| Dec 31, 2025 | 115.15% |
| Sep 30, 2025 | 4.63% |
| Jun 30, 2025 | 84.16% |
| Mar 31, 2025 | 192.48% |
| Dec 31, 2024 | 28.97% |
| Sep 30, 2024 | -145.07% |
| Jun 30, 2024 | -133.56% |
| Mar 31, 2024 | -30.17% |
| Dec 31, 2023 | 27.24% |
| Sep 30, 2023 | 56.18% |
| Jun 30, 2023 | 24.90% |
| Mar 31, 2023 | -4.75% |
| Dec 31, 2022 | -103.95% |
| Sep 30, 2022 | -30.58% |
| Jun 30, 2022 | 16.27% |
| Mar 31, 2022 | -176.47% |
| Dec 31, 2021 | -107.38% |
| Sep 30, 2021 | -119.25% |